BioNotebook: Second Genome/Pfizer, Merck/Agenus, Endo/Somar, Parion/Gilead, Lightstone Ventures, Kite Pharma, five IPO updates

Second Genome, Pfizer research microbiome; Deal or no deal – Merck/Agenus, Endo/Somar, Parion/Gilead begin, end relationships; Lightstone initiates new VC fund; Kite Pharma raises private cash; and GlobeImmune, Mapi-Pharma, Scynexis, Aldeyra, Ambrx move toward IPOs.

Second Genome, Pfizer research microbiome; Deal or no deal – Merck/Agenus, Endo/Somar, Parion/Gilead begin, end relationships; Lightstone initiates new VC fund; Kite Pharma raises private cash; and GlobeImmune, Mapi-Pharma, Scynexis, Aldeyra, Ambrx move toward IPOs.

Second Genome, Pfizer search microbiome for obesity targets

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category